KR102359191B1 - 3-데속시 유도체 및 이의 약제학적 조성물 - Google Patents

3-데속시 유도체 및 이의 약제학적 조성물 Download PDF

Info

Publication number
KR102359191B1
KR102359191B1 KR1020187028967A KR20187028967A KR102359191B1 KR 102359191 B1 KR102359191 B1 KR 102359191B1 KR 1020187028967 A KR1020187028967 A KR 1020187028967A KR 20187028967 A KR20187028967 A KR 20187028967A KR 102359191 B1 KR102359191 B1 KR 102359191B1
Authority
KR
South Korea
Prior art keywords
disease
compound
present
liver
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028967A
Other languages
English (en)
Korean (ko)
Other versions
KR20180117702A (ko
Inventor
로베르토 펠리치아리
안티모 지오이엘로
Original Assignee
인터셉트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터셉트 파마슈티컬즈, 인크. filed Critical 인터셉트 파마슈티컬즈, 인크.
Publication of KR20180117702A publication Critical patent/KR20180117702A/ko
Application granted granted Critical
Publication of KR102359191B1 publication Critical patent/KR102359191B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
KR1020187028967A 2016-03-11 2017-03-07 3-데속시 유도체 및 이의 약제학적 조성물 Active KR102359191B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306914P 2016-03-11 2016-03-11
US62/306,914 2016-03-11
PCT/US2017/021194 WO2017156024A1 (en) 2016-03-11 2017-03-07 3-desoxy derivative and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
KR20180117702A KR20180117702A (ko) 2018-10-29
KR102359191B1 true KR102359191B1 (ko) 2022-02-04

Family

ID=59787771

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028967A Active KR102359191B1 (ko) 2016-03-11 2017-03-07 3-데속시 유도체 및 이의 약제학적 조성물

Country Status (20)

Country Link
US (3) US10815267B2 (enExample)
EP (1) EP3426348B1 (enExample)
JP (1) JP6892457B2 (enExample)
KR (1) KR102359191B1 (enExample)
CN (1) CN108883305B (enExample)
AR (1) AR107864A1 (enExample)
AU (1) AU2017229481B2 (enExample)
BR (1) BR112018068278B1 (enExample)
CA (1) CA3016875C (enExample)
EA (1) EA038632B1 (enExample)
ES (1) ES2874682T3 (enExample)
IL (1) IL261548B (enExample)
MX (1) MX384800B (enExample)
PH (1) PH12018501956A1 (enExample)
PL (1) PL3426348T3 (enExample)
PT (1) PT3426348T (enExample)
SG (1) SG11201807784SA (enExample)
SI (1) SI3426348T1 (enExample)
TW (1) TWI772289B (enExample)
WO (1) WO2017156024A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703717SA (en) 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CN107249594A (zh) 2015-02-11 2017-10-13 英安塔制药有限公司 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
SG10201910670RA (en) 2015-03-31 2020-01-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
ES2898705T3 (es) 2015-10-07 2022-03-08 Intercept Pharmaceuticals Inc Moduladores de los receptores farnesoides x
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PT3426348T (pt) 2016-03-11 2021-06-28 Intercept Pharmaceuticals Inc Derivado de 3-desoxi e composições farmacêuticas do mesmo
JP7057783B2 (ja) 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニル尿素胆汁酸誘導体の調製方法
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
BR112019020780A2 (pt) 2017-04-07 2020-04-28 Enanta Pharm Inc processo para preparação de derivados de ácido biliar de carbamato de sulfonila
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2022152773A1 (en) * 2021-01-14 2022-07-21 Enyo Pharma Method for treating chronic kidney diseases
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CA3249500A1 (en) * 2022-04-21 2023-10-26 Intercept Pharmaceuticals, Inc. USES OF FARNESOID X RECEPTOR AGONISTS
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2712617T1 (sl) * 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
US20130261317A1 (en) * 2010-09-27 2013-10-03 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
MX354156B (es) 2011-12-29 2018-02-15 Novo Nordisk As Dipeptido que comprende un aminoacido no proteogenico.
PL2997035T3 (pl) * 2013-05-14 2018-10-31 Intercept Pharmaceuticals, Inc. 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x
PT3149019T (pt) * 2014-05-29 2020-02-19 Bar Pharmaceuticals S R L Derivados de colano para utilização no tratamento e/ou na prevenção de doenças mediadas por fxr e tgr5/gp-bar1
HK1252688A1 (zh) * 2015-08-07 2019-05-31 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
PT3426348T (pt) 2016-03-11 2021-06-28 Intercept Pharmaceuticals Inc Derivado de 3-desoxi e composições farmacêuticas do mesmo

Also Published As

Publication number Publication date
JP6892457B2 (ja) 2021-06-23
CN108883305B (zh) 2021-03-16
IL261548B (en) 2021-02-28
PL3426348T3 (pl) 2022-01-03
CN108883305A (zh) 2018-11-23
CA3016875C (en) 2023-08-22
TWI772289B (zh) 2022-08-01
MX2018010983A (es) 2019-01-21
BR112018068278A2 (pt) 2019-04-02
NZ745980A (en) 2025-03-28
IL261548A (en) 2018-11-29
US20210101927A1 (en) 2021-04-08
EP3426348A1 (en) 2019-01-16
CA3016875A1 (en) 2017-09-14
ES2874682T3 (es) 2021-11-05
SI3426348T1 (sl) 2021-11-30
KR20180117702A (ko) 2018-10-29
AR107864A1 (es) 2018-06-13
EP3426348B1 (en) 2021-05-05
BR112018068278B1 (pt) 2023-12-19
US11319337B2 (en) 2022-05-03
PH12018501956A1 (en) 2019-06-17
WO2017156024A1 (en) 2017-09-14
US20190002493A1 (en) 2019-01-03
PT3426348T (pt) 2021-06-28
AU2017229481B2 (en) 2022-06-16
SG11201807784SA (en) 2018-10-30
EA038632B1 (ru) 2021-09-27
EA201892007A1 (ru) 2019-01-31
US10815267B2 (en) 2020-10-27
JP2019507781A (ja) 2019-03-22
AU2017229481A1 (en) 2018-09-20
MX384800B (es) 2025-03-14
EP3426348A4 (en) 2019-11-20
US20170260225A1 (en) 2017-09-14
TW201734031A (zh) 2017-10-01
HK1259145A1 (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
KR102359191B1 (ko) 3-데속시 유도체 및 이의 약제학적 조성물
US12291549B2 (en) Farnesoid X receptor modulators
EP3848038B1 (en) 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
HK1259145B (zh) 3-脱氧衍生物及其药物组合物
HK1253558B (zh) 法尼醇x受体调节剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181008

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200306

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211112

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220121

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220128

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220128

End annual number: 3

Start annual number: 1

PG1601 Publication of registration